Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Objective The aim of this study was to investigate the efficacy and efficiency of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain. Of major interest were the evaluation of the influence the treatment had on pain and on quality of life as well as the subjective assessment of positive effects and side effects by the study participants. Methods The placebo-controlled double-blinded pilot study was divided into a 14 week cross-over period (two 4 week medication phases plus wash-out phases) followed by a 16 week medication switch period with free choice of the study drugs (drug A and drug B) by the study participants. The principal inclusion criterion was chronic therapy-resistant pain in causal relationship with a pathologic status of the skeletal and locomotor system. The study participants chose the dosage of the study drug themselves (between 1 und 4 capsules/day, in the case of nabilone this corresponds to (1/4)-1 mg/day). Pain intensity was assessed by a visual analogue scale (VAS), quality of life by the Mezzich and Cohen QOL-score. Results Altogether, 30 patients were included and analyzed. From the results, it is obvious that throughout the cross-over periods the nabilone treatment was superior (medians [25%-; 75%-percentiles]: nabilone/placebo): decrease of the average spinal pain intensity within the last 4 weeks (DeltaVAS) 0.9 [0.0; 2.0] / 0.5 [0.0; 1.7], decrease of the current spinal pain intensity (DeltaVAS) 0.6 [0.0; 2…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These processes have a number of characteristics in common with chronic neuropathic pain or fibromyalgia, chronic conditions for which nabilone has been tested with encouraging results [15–17].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [15]
In the citing paper
“Benefits of an add-on treatment with nabilone have nonetheless been noted in patients with chronic therapy-resistant pain (observed in causal relationship with a pathological status of the skeletal and locomotor system).167”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [167]
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“CB 2-Rezeptoren werden darüber hinaus insbesondere von Immunzellen (Leukozyten, Milz, Tonsillen) exprimiert [4, 5].”
Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain
Wager, T. D., Rilling, J. K., Smith, E. E., Sokolik, A., Casey, K. L., Davidson, R. J., Kosslyn, S. M., Rose, R. M., & Cohen, J. D. (2004) · Science · doi:10.1126/science.1093065 · Cited by 1,992 · cited 2×
“10% der Studienteilnehmer handelt, was durch die bei Schmerzpatienten bekannte Empfänglichkeit für Placeboeffekte gut erklärbar ist [23].”
BackgroundPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470 · cited 3×
“CB 2-Rezeptoren werden darüber hinaus insbesondere von Immunzellen (Leukozyten, Milz, Tonsillen) exprimiert [4, 5].”
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · cited 1×
“Vergleicht man die Ergebnisse der gegenständlichen Studie mit denen der derzeit aussagekräftigsten doppelblinden placebokontrollierten Studie mit Cannabis bei 667 randomisierten MS-Patienten zur Behandlung der MS-bedingten Symptome Schmerz und Spastizität (CAMS-Studie) [25], so lassen sich durchaus Übereinstimmungen f…”
BackgroundCannabinoids as Therapeutic Agents
(2019) · Chapman & Hall/CRC eBooks · doi:10.1201/9780429260667 · Cited by 311
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283
Azad, S. C., Eder, M., Marsicano, G., Lutz, B., Zieglgänsberger, W., & Rammes, G. (2003) · Learning & Memory · doi:10.1101/lm.53303 · Cited by 220 · cited 1×
“Darüber hinaus gibt es Daten zur antispastischen und analgetischen Wirksamkeit von Cannabinoiden insgesamt und Nabilone im Speziellen, die auf eine indirekte Aktivierung von gabaergen Neuronen im Zentralnervensystem, besonders im Rückenmark, und die Beeinflussung dopaminerger Neurone zurück zu führen sein dürfte [11–1…”
BackgroundConti, S., Costa, B., Colleoni, M., Parolaro, D., & Giagnoni, G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704466 · Cited by 190 · cited 1×
“Diese bekannten physiologischen Einflüsse des Cannabinoidsystems bilden eine plausible Grundlage für klinische Wirkungen auf verschiedene Schmerzformen, wie neuropathischer Schmerz [16], Pruritus [17], Schmerz und Muskelverkrampfung bei Multipler Sklerose (MS) [14], Migräne, Kopfschmerz und Schmerzen am Bewegungsappar…”
BackgroundCannabinoids and multiple sclerosis
Pertwee, R. G. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00255-3 · Cited by 181
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142 · cited 1×
“Diese bekannten physiologischen Einflüsse des Cannabinoidsystems bilden eine plausible Grundlage für klinische Wirkungen auf verschiedene Schmerzformen, wie neuropathischer Schmerz [16], Pruritus [17], Schmerz und Muskelverkrampfung bei Multipler Sklerose (MS) [14], Migräne, Kopfschmerz und Schmerzen am Bewegungsappar…”
Background
Research works printed but not linked: 1
- Grotenhermer F (2001) Pharmakologie, Toxikologie und therapeutisches Potential von Cannabis und Cannabinoiden. Huber, Bern
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
New Insights into the Placebo and Nocebo Responses
Enck, P., Benedetti, F., & Schedlowski, M. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.030 · Cited by 531
“The FCP has been used occasionally in optimizing dosage of drugs (Perkins et al., 1997; Pinsger et al., 2006) in clinical trials.”
Hill, K. P. (2015) · JAMA · doi:10.1001/jama.2015.6199 · Cited by 508
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397
Metadata
- Authors
- Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W.
- Affiliations
- Johannes Kepler University of Linz (AT)
- Medical University of Vienna (AT)
- Corresponding author
- Pinsger, Martin
- Venue
- Wiener klinische Wochenschrift
- Published
- 2006-06
- Volume
- 118
- Issue
- 11-12
- Pages
- 327-335
- ISSN
- 0043-5325 (ISSN-L)
- 1613-7671
- OpenAlex
- W1494478174
- Cited by
- 96
- References
- 26
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 14 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 6
- FWCI
- 2.51
- Type
- journal article
- Language
- de
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Wiener klinische Wochenschrift (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- chronic pain, adjunctive therapy, treatment-resistant pain, spinal pain, headache, quality of life, pain intensity, adverse effects, crossover design, cost-effectiveness, patient satisfaction, physician satisfaction
- MeSH terms
- Cannabinoids, Chronic Disease, Double-Blind Method, Female, Humans, Male, Middle Aged, Pain, Pain Measurement, Quality of Life, Dronabinol, Anti-Anxiety Agents, Placebo Effect, Treatment Outcome, Chemotherapy, Adjuvant, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie. https://app.cochat.ai/papers/10.1007/s00508-006-0611-4
- The paper
- Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006). Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-006-0611-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.